According to Schulz et al. [30], five biomarkers showed an elevated accuracy in differentiating 16 CBS patients from 38 PSP patients and 20 healthy controls, namely CSF NfH (AUC 0.9), S100B (AUC 0.9), CSF ubiquitin C-terminal hydrolase-1 UCHL-1 (AUC 0.84), CSF Glial Fibrillary Acid Protein (GFAP) (AUC 0.8), CSF soluble triggering receptor expressed on myeloid cells (sTREM2) (AUC 0.96), and serum S100 calcium-binding protein B (S100B) (AUC 0.84). The gene discussed is GFAP; the disease is supranuclear palsy, progressive, 1.